Aarti Pharmalabs Limited
All news and filings related to Aarti Pharmalabs Limited.
View all news & filings- Low impact
Aarti Pharmalabs: Trading Window Closed from Oct 1, 2026, for Q2 FY27 Results
Aarti Pharmalabs Limited will close its trading window from October 01, 2026. The closure is in effect until 48 hours after the declaration of financial results for the quarter ending September 30, 2026. The board meeting date for approving these results will be announced later.
Read the summary - Medium impact
Aarti Pharmalabs: Board Changes Approved at 7th AGM
Aarti Pharmalabs announced board changes post-AGM on Sep 22, 2026. Shri Rajendra Gogri ceased as Director. Smt. Hetal Gogri Gala re-designated to Whole-time Director, and Shri Rashesh C. Gogri appointed as Managing Director, both effective Oct 1, 2026.
Read the summary - Medium impact
Aarti Pharmalabs AGM: Financials Adopted, Dividend Approved, Key Management Changes Confirmed
Aarti Pharmalabs Limited held its 7th AGM on September 22, 2026. Shareholders approved the FY26 financial statements and a final dividend of ₹2 per share. Key management changes include Smt. Hetal Gogri Gala's designation change to Whole-time Director and Shri Rashesh C. Gogri's appointment as Managing Director, both effective October 1, 2026.
Read the summary - Medium impact
Aarti Pharmalabs Limited Holds 7th AGM on Sep 22, 2026, Presents Investor Update
Aarti Pharmalabs Limited held its 7th AGM on Sep 22, 2026, presenting its investor update. For FY26, standalone revenue was ₹1,798 crore and consolidated revenue was ₹18,194 crore. The company is investing ₹400 crore in the Atali Greenfield project and ₹210 crore in Tarapur Brownfield expansion. It targets 15-18% revenue and EBITDA CAGR over the next 3-4 years.
Read the summary - Medium impact
Aarti Pharmalabs Holds 7th AGM: Declares ₹2 Dividend, Approves Director Changes
Aarti Pharmalabs Limited held its 7th AGM on September 22, 2026. The company declared a final dividend of ₹2 per equity share for FY26. Key management changes include Smt. Hetal Gogri Gala moving to Whole-time Director and Shri. Rashesh C. Gogri becoming Managing Director, both effective October 1, 2026. Financial statements for FY26 were adopted.
Read the summary - Medium impact
Aarti Pharmalabs to Challenge ₹59.5 Crore Stamp Duty Order
Aarti Pharmalabs Limited received an order from the Superintendent of Stamps, Gujarat, levying ₹59.50 Crore in stamp duty and penalties related to its demerger. The company plans to challenge this order, citing strong legal grounds.
Read the summary - Low impact
Aarti Pharmalabs: Sr. General Manager G.M. Naidu Resigns
Shri G.M. Naidu, Manufacturing/ Sr. General Manager at Aarti Pharmalabs Limited, has resigned. His resignation is effective August 31, 2026, due to personal commitments. He submitted his resignation on June 10, 2026.
Read the summary - Low impact
Aarti Pharmalabs Announces 7th AGM on Sep 22, 2026, for FY25-26 Annual Report
Aarti Pharmalabs Limited will hold its 7th Annual General Meeting on September 22, 2026, at 11:00 AM IST via Video Conference. The company has also dispatched its Annual Report for the Financial Year 2025-26.
Read the summary - Low impact
Aarti Pharmalabs submits Business Responsibility and Sustainability Report for FY26
Aarti Pharmalabs Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's operations, market reach, and sustainability initiatives, in compliance with SEBI regulations. It is available on the company's website.
Read the summary - Low impact
Aarti Pharmalabs Announces 7th AGM on Sept 22, 2026, Encloses Annual Report FY26
Aarti Pharmalabs will hold its 7th Annual General Meeting on September 22, 2026, via video conference. The company has released its Annual Report for FY 2025-26, detailing its business segments, investments in capacity and R&D, and sustainability initiatives. The report is available on the company's website.
Read the summary - Low impact
Aarti Pharmalabs Limited to hold 7th AGM on Sep 22, 2026; sets Sep 15 as record date for final dividend.
Aarti Pharmalabs Limited will hold its 7th AGM on September 22, 2026, via VC/OAVM. The record date for final dividend payment for FY2025-26 is set for September 15, 2026. Newspaper advertisements were published on August 18, 2026.
Read the summary - Medium impact
Aarti Pharmalabs sets Sep 15, 2026 as Record Date for ₹2 Final Dividend for FY26
Aarti Pharmalabs has set September 15, 2026, as the Record Date for its Final Dividend of ₹2.00 per equity share (40%) for FY 2025-26. The dividend payment is subject to shareholder approval at the AGM on September 22, 2026, with payment expected by October 20, 2026.
Read the summary - Low impact
Aarti Pharmalabs Uploads Q1 FY27 Earnings Call Recording
Aarti Pharmalabs Limited has uploaded the audio recording of its Q1 FY27 earnings conference call. The call discussed the unaudited financial results for the quarter ended June 30, 2026. The recording is available on the company's website.
Read the summary - High impact
Aarti Pharmalabs Files Q1 FY27 Investor Presentation
Aarti Pharmalabs Limited released its Q1 FY27 investor presentation. Standalone revenue was ₹5,346 million, with EBITDA at ₹1,327 million (24.82% margin). Consolidated revenue was ₹5,358 million, with EBITDA at ₹1,326 million (24.75% margin). PAT stood at ₹713 million standalone and ₹761 million consolidated. The company targets 15-18% Revenue & EBITDA CAGR and plans ₹149 crore capex for Atali Block 2.
Read the summary - Low impact
Aarti Pharmalabs Publishes Q1 FY27 Financial Results in Newspapers
Aarti Pharmalabs Limited has published its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The results were announced in the Financial Express and Loksatta - Jansatta on August 09, 2026.
Read the summary - Low impact
Aarti Pharmalabs: Non-Executive Director Rajendra Gogri Retires by Rotation at AGM
Mr. Rajendra Vallabhaji Gogri, Non-Executive Director of Aarti Pharmalabs Limited, will retire by rotation at the upcoming AGM. He has decided not to seek re-appointment due to personal commitments.
Read the summary - High impact
Aarti Pharmalabs Approves Q1 FY27 Results, Capex of ₹149 Crore, and Key Management Changes
Aarti Pharmalabs reported Q1 FY27 results with standalone revenue of ₹534.59 crore and net profit of ₹71.31 crore. Consolidated revenue was ₹535.80 crore with net profit of ₹76.14 crore. The company approved a ₹149 crore capex for capacity expansion and key management changes, appointing Rashesh C. Gogri as Managing Director and Hetal Gogri Gala as Executive Director, effective October 1, 2026.
Read the summary - Medium impact
Aarti Pharmalabs Board Approves Q1 FY27 Results, Director Role Changes, and Capex
Aarti Pharmalabs reported Q1 FY27 results with standalone revenue at ₹53,458.78 Lakhs and consolidated revenue at ₹53,579.69 Lakhs. Net profit after tax stood at ₹7,130.66 Lakhs (standalone) and ₹7,614.27 Lakhs (consolidated). The board approved changes in director roles, effective October 1, 2026, and a ₹149 Crore capex for capacity expansion.
Read the summary - High impact
Aarti Pharmalabs Board Approves Q1 FY27 Results, Key Management Changes & Capex
Aarti Pharmalabs reported Q1 FY27 results with net profit of ₹71.31 crore (standalone) and ₹76.14 crore (consolidated). The board approved Rashesh C. Gogri as MD and Hetal Gogri Gala as Executive Director from Oct 1, 2026. A capex of ₹149 crore for intermediate block capacity was also approved.
Read the summary - Low impact
Aarti Pharmalabs Schedules Q1 FY27 Earnings Conference Call for August 10
Aarti Pharmalabs Limited will host an Earnings Conference Call on August 10, 2026, at 4:00 PM IST to discuss its Q1 FY27 financial results. Key management personnel will participate.
Read the summary - Low impact
Aarti Pharmalabs Files Certificate Under SEBI Regulations for Q1 FY27
Aarti Pharmalabs Limited has filed a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The certificate was issued by the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
Read the summary - Medium impact
Aarti Pharmalabs inaugurates new manufacturing block, boosting Xanthine capacity to 9600 TPA.
Aarti Pharmalabs inaugurated a new manufacturing block at Tarapur Unit 5, expanding Xanthine derivatives capacity by 3600 TPA to a total of 9600 TPA. This positions the company among the top three global producers. Trial production has begun, with full ramp-up expected in the coming quarters.
Read the summary - Low impact
Aarti Pharmalabs Allots 22,062 Equity Shares Under ESOP Plan
Aarti Pharmalabs Limited allotted 22,062 equity shares under its PSOP 2023 plan. This increases the company's paid-up equity share capital to ₹45.34 crore, comprising 9.07 crore shares.
Read the summary - Low impact
Aarti Pharmalabs Limited: Trading Window Closed from July 1, 2026, for Q1 FY27 Results
Aarti Pharmalabs Limited will close its trading window from July 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter ending June 30, 2026. The Board Meeting date for approving these results will be announced later.
Read the summary - Medium impact
Aarti Pharmalabs Q4 FY26 Earnings Call Transcript Released; Board Declares Dividend
Aarti Pharmalabs Q4 FY26 revenue rose 9% YoY to ₹580 Cr. Full-year revenue was ₹1798 Cr. The board declared a final dividend of ₹2 per share. The company targets 15-18% revenue and EBITDA growth over the next 3-4 years, with CDMO expected to grow 40-50% in FY27. Capex of ₹400 Cr planned for FY27.
Read the summary - Low impact
Aarti Pharmalabs Publishes Audited Financial Results for FY26 in Newspapers
Aarti Pharmalabs Limited published its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The publications were made in the Financial Express and Loksatta – Jansatta newspapers on May 27, 2026.
Read the summary - Low impact
Aarti Pharmalabs: Audio Recording of Q4 FY26 Earnings Call Uploaded
Aarti Pharmalabs Limited has made the audio recording of its Q4 FY26 earnings conference call available online. The call discussed the audited financial results for the quarter and full year ended March 31, 2026. The recording can be accessed via the company's website.
Read the summary - Medium impact
Aarti Pharmalabs Q4FY26 Investor Presentation Released; FY27 Capex Outlook Similar to FY26
Aarti Pharmalabs released its Q4 FY26 Investor Presentation. Standalone FY26 revenue was ₹17,976 million, with EBITDA at ₹4,061 million. Consolidated FY26 revenue was ₹18,194 million, with EBITDA at ₹4,024 million. The company targets 15-18% Revenue & EBITDA CAGR over the next 3-4 years. FY26 Capex was ~₹400 crore, with a similar outlook for FY27.
Read the summary - Medium impact
Aarti Pharmalabs Board Approves FY26 Audited Results, Recommends Rs. 2 Dividend
Aarti Pharmalabs Limited's Board approved audited standalone and consolidated financial results for FY26. The company reported a standalone net profit of ₹17,620.20 lakhs and consolidated net profit of ₹17,470.73 lakhs for the full year. A final dividend of ₹2 per equity share was recommended. Sachin Patil and Rajendra Pagare were appointed as Senior Management.
Read the summary - Medium impact
Aarti Pharmalabs Approves FY26 Audited Results, Recommends ₹2 Dividend, Appoints New Senior Management
Aarti Pharmalabs Limited declared its audited financial results for FY26. The company recommended a final dividend of ₹2 per equity share. Smt. Ketki D. Visariya was re-appointed Cost Auditor and Manish Modi & Associates as Internal Auditor for FY27. Sachin Patil and Rajendra Pagare were appointed as Senior Management Personnel.
Read the summary - Medium impact
Aarti Pharmalabs Approves FY26 Audited Results and Recommends Rs. 2 Dividend
Aarti Pharmalabs Limited approved audited financial results for FY26 and recommended a final dividend of ₹2 per equity share. The company also re-appointed its Cost and Internal Auditors for FY27 and designated two key personnel as Senior Management.
Read the summary - Medium impact
Aarti Pharmalabs Approves Audited Results, Recommends ₹2 Dividend, Appoints Senior Management
Aarti Pharmalabs approved its audited financial results for Q4 FY26 and the full year. The company recommended a final dividend of ₹2 per share. Smt. Ketki D. Visariya was re-appointed Cost Auditor, and Manish Modi & Associates were re-appointed Internal Auditors for FY27. Sachin Patil and Rajendra Pagare were appointed as Senior Management Personnel.
Read the summary - Low impact
Aarti Pharmalabs to attend 360 ONE Capital Conference on May 28, 2026
Aarti Pharmalabs Limited will attend the 360 ONE Capital Conference - Trinity 2026 on May 28, 2026. The company will engage in one-on-one and group meetings with investors and analysts to discuss its business operations.
Read the summary - Low impact
Aarti Pharmalabs Schedules Q4 FY26 Earnings Conference Call for May 26
Aarti Pharmalabs Limited will hold an Earnings Conference Call on May 26, 2026, at 4:00 PM IST to discuss Q4 FY26 financial results. Key management personnel will participate.
Read the summary - Low impact
Aarti Pharmalabs Files SEBI Regulation 74(5) Certificate for Q4FY26
Aarti Pharmalabs Limited submitted its SEBI Regulation 74(5) certificate for the quarter ended March 31, 2026. The company's RTA confirmed the dematerialisation of securities and updates to the register of members within prescribed timelines.
Read the summary - Low impact
Aarti Pharmalabs Publishes Newspaper Ad for 'Saksham Niveshak' Campaign
Aarti Pharmalabs Limited published newspaper advertisements on April 07, 2026, for its 'Saksham Niveshak' campaign. The ads appeared in Financial Express (English) and Loksatta-Jansatta (Gujarati). Information is also available on the company's website.
Read the summary - Low impact
Aarti Pharmalabs Launches 'Saksham Niveshak' Campaign for Unclaimed Dividends
Aarti Pharmalabs is participating in the 'Saksham Niveshak' campaign (April 01 - July 09, 2026) to help shareholders claim unpaid dividends. Shareholders must update KYC and bank details by July 09, 2026, to receive payments and avoid share transfer to IEPF.
Read the summary - Low impact
Aarti Pharmalabs Unit-IV US FDA Inspection Concludes with 1 Procedural Observation
Aarti Pharmalabs Limited's Unit-IV facility in Tarapur underwent a US FDA inspection concluding on March 27, 2026. The inspection resulted in one procedural observation via a Form 483. The company will submit corrective actions within the stipulated period.
Read the summary - Low impact
Aarti Pharmalabs: Trading Window Closed from April 1, 2026, for FY26 Financial Results
Aarti Pharmalabs Limited will close its trading window from April 1, 2026. This closure is in effect until 48 hours after the declaration of financial results for the quarter and financial year ending March 31, 2026. The board meeting date for approving these results will be announced later.
Read the summary - Low impact
Aarti Pharmalabs Unit VI Suffers Minor Chemical Leak; Operations Restored
A minor chemical leak occurred at Aarti Pharmalabs Unit VI on March 22, 2026, during chemical loading. 22 workers were hospitalized for observation, with most discharged. Operations were restored within 24 hours. No loss of life or property damage reported. Investigation is ongoing.
Read the summary - Medium impact
Aarti Pharmalabs Q3 FY26 Earnings Call Transcript Released; Interim Dividend Declared
Aarti Pharmalabs released its Q3 FY26 earnings call transcript. Q3 standalone revenue was ₹425 crore, with profit after tax at ₹44 crore. An interim dividend of ₹1.5 per share was declared. The company expects FY26 EBITDA to be flat to marginally growing due to Atali plant delays and API softness. Xanthine expansion targets mechanical completion by March 2026.
Read the summary - Low impact
Aarti Pharmalabs Limited Clarifies Delay in Disclosure to BSE
Aarti Pharmalabs Limited clarified a delay in submitting a corporate announcement to the BSE. The delay was attributed to the concerned official being on leave from February 3rd to February 5th, with the matter only being addressed upon their return. The company seeks to have this clarification recorded by the exchange.
Read the summary - Low impact
Aarti Pharmalabs: Newspaper Publication for Q3 & 9M FY26 Unaudited Financial Results
Aarti Pharmalabs Limited published its Q3 and 9M FY26 unaudited financial results on February 11, 2026. The results were announced in the Financial Express and Loksatta – Jansatta.
Read the summary - Low impact
Aarti Pharmalabs: Audio Recording of Q3 FY26 Earnings Conference Call Uploaded
Aarti Pharmalabs Limited has made the audio recording of its Q3 FY26 earnings conference call available online. The call focused on the financial results for the third quarter and nine months ended December 31, 2025. The recording can be accessed on the company's website.
Read the summary - Low impact
Aarti Pharmalabs Corrects Dividend Financial Year to FY26
Aarti Pharmalabs Limited corrected its dividend record date announcement. The dividend declared is for Financial Year 2025-26, correcting a prior mention of FY 2024-25. This clarification was issued on February 10, 2026.
Read the summary - Medium impact
Aarti Pharmalabs Q3 FY26 Investor Presentation: Revenue ₹4,253 Cr, EBITDA ₹1,030 Cr
Aarti Pharmalabs Limited's Q3 FY26 investor presentation shows standalone revenue of ₹4,253 crore and EBITDA of ₹1,030 crore. Year-to-date revenue is ₹12,179 crore. The company is expanding Xanthine capacity to 9,000+ MTPA and targeting 20-25% global market share. Greenfield capex at Atali is expected to ramp up by Q4 FY26, and brownfield expansion at Tarapur is slated for Q4 FY26.
Read the summary - Medium impact
Aarti Pharmalabs Fixes Feb 16 as Record Date for Interim Dividend
Aarti Pharmalabs declared an interim dividend of ₹1.5 per equity share for FY24-25. The record date for this dividend payment has been set as February 16, 2026.
Read the summary - Medium impact
Aarti Pharmalabs Declares Interim Dividend of ₹1.5/Share, Approves Q3 FY26 Results
Aarti Pharmalabs declared an interim dividend of ₹1.50 per share for FY25-26. The Board approved unaudited financial results for Q3 and nine months ended Dec 31, 2025. Standalone revenue from operations for Q3 was ₹255.28 crore and consolidated was ₹378.74 crore. The record date for the dividend is Feb 16, 2026.
Read the summary - Medium impact
Aarti Pharmalabs declares interim dividend of ₹1.5 per share; Record date Feb 16
Aarti Pharmalabs declared an interim dividend of ₹1.50 per equity share for FY25-26. The record date for dividend payment is February 16, 2026. The Board also approved the unaudited financial results for the quarter and nine months ended December 31, 2025.
Read the summary - Low impact
Aarti Pharmalabs fined ₹2.6 Lakhs by CGST, claims no material impact
Aarti Pharmalabs Limited received a penalty of ₹2.60 Lakhs from CGST and Central Excise, Vapi. An alleged demand of ₹31.16 Lakhs was issued for FY23-24 due to input tax credit discrepancies. The company asserts no material impact on its operations or financials.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio